NanoViricides inks deal for shingles study

NanoViricides, Inc. (NYSE:NNVC) said today that it inked a deal with SUNY Upstate Medical University for the evaluation of its nanovirivides drug candidates against varicella zoster virus, also called the shingles virus.

The goal of these in vitro, ex vivo, and in vivo studies will be to help select a clinical drug development candidate for toxicology and safety evaluation intended for future clinical trials , according to the Shelton, Connecticut-based company.

Researchers will evaluate the efficacy of the company’s nanoviricides antiviral agents against the shingles virus in human cells, as well as human skin organ cultures. A model developed by the lead researacher, Jennifer Moffat, demonstrates behavior similar to the skin lesions caused by shingles in human patients.

Get the full story at our sister site, Drug Delivery Business News.

The post NanoViricides inks deal for shingles study appeared first on MassDevice.

from MassDevice http://ift.tt/2fro3ZO